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INTRODUCTION
Bone is the most common metastatic site for prostate cancer which affects approximately 70% of patients with advanced disease (1) . Despite this clinical importance, the exact molecular mechanism of the bone-specific metastasis has not been clearly defined. The growth of the tumor cells in the bone is generally slow and they often become dormant until an appropriate microenviroment is established for their re-growth. According to the recent cancer stem cell theory, which still remains a hypotheses, recurrent tumor must arise from a dormant tumor stem cell (2) . However, the precise mechanism of dormancy is virtually unknown, and identifying the responsible factors and understanding the underlining mechanism are crucial for developing a novel therapeutic approach. Our recent preliminary data suggest that BMP7 (bone morphogenetic protein 7) which is secreted from bone stromal cells is able to induce senescence to prostate tumor cells and that this induction is mediated by activation of the tumor metastasis suppressor gene, NDRG1 (N-myc downstream regulated gene 1). Therefore, we hypothesize that a prostatic tumor stem cell becomes dormant in the bone through the BMP7-mediated activation of p38 and NDRG1. To accomplish Task 1 (a)-(c), we first examined the effect of BMP7 and Wnt on the growth of prostate cancer cells. As shown in Figure 1 , BMP7 significantly suppressed the growth, while Wnt3a significantly promoted the prostate cancer cell growth. Furthermore, up-regulation of NDRG1 counteracted the effect of Wnt3a on the cancer cell growth, suggesting that the balance of BMP and Wnt signalings may determine whether the tumor cells stay in growth arrest or proliferate. Next, we isolated cancer stem cells (CSCs, CD24-/CD44+/CD133+) from PC3mm cells that were labeled with the luciferase gene. Our result of serial dilution assay for tumor initiating ability in animals indicates that the CSC population was significantly more tumorigenic than non-stem cells (CD24 + /CD44 -/CD133 -) ( Figure 2A ). We also found that BMP7 was able to activate p38, NDRG1 and p21 ( Figure  2B -2D) in CSCs, and that the induction of NDRG1 and p21 was mediated by p38 ( Figure 2C and 2D ). In addition, BMP7 significantly inhibited the sphere forming ability of CSCs; however, these cells regained the growth ability after withdrawal of BMP7 from the medium ( Figure 2E ). Furthermore, BMP7 was also able to induce senescence in CSCs ( Figure 2F ; +/+) with concomitant activation of NDRG1 and p21 ( Figure 2G ; +/+ and 2H; +/+). Of note, the BMP7-mediated induction of senescence as well as the activation of NDRG1 and p21 was reversed after withdrawal of BMP7 ( Figure 2F ; +/-, 2G; +/-, and 2H; +/-). Similarly, up-regulation of NDRG1 in CSCs by using PC3mm cell line which had tetracycline-inducible NDRG1 significantly suppressed the sphere formation and induced senescence, while de-induction of NDRG1 by withdrawal of tetracycline reversed this effect ( Figure 2I and 2J). These results suggest that BMP7 was able to induce reversible senescence in CSCs through activation of p38, p21 and NDRG1. To accomplish Task 1 (d), we examined whether BMP7 activates MET program in prostate cancer cells. We found that BMP7 significantly reduced vimentin (mesenchymal marker) expression while it significantly augmented E-cadherin (epithelial marker) expression ( Figure 3A, B) . Moreover, upregulation of NDRG1 induced similar MET effect ( Figure 3C, D) , suggesting that BMP7-NDRG1 axis induced MET in prostate cancer cells. Therefore, we now have identified that BMP7-p38-NDRG1 axis plays critical roles in inducing senescence and MET in CSCs.
BODY
To accomplish Task 1, we also examined the effect of Wnt pathway on BMP7-induced senescence, and cancer stem cell population. We found that BMP7significantly suppressed the Wnt 3-mediated self-renewal of CSCs (Figure 4 A, B ). In addition, BMP7 was able to induce senescence in cancer cells even in the presence of Wnt ligand (Figure 4 C) .
Task 2. To examine the effect of BMP7 on tumor stem cell in vivo (a) Co-inject tumor stem cell and bone marrow stromal cell into nude mouse using calcium-phosphate scaffold and examine the effect of BMP7 on the tumor growth. (b) Examine the effect of BMP7 on dormancy by injecting tumor stem cell via intracardiac followed by directly injecting BMP7 intravenously.
To accomplish Task 2, we isolated tumor stem cells from PC3mm labeled with luciferase gene and these cells were seeded onto CaP scaffolds with HS5 (bone stromal cells), and then these constructs were implanted into the upper back of nude mice. Recombinant human BMP7 was peritumorally injected daily after implantation. Tumor growth was monitored weekly by bioluminescent imaging. We found that BMP7 treatment significantly suppressed the tumor growth ( Figure 4A and B). To further examine the effect of BMP7 on the tumor growth in bone, CSCs were injected into tibiae of mice with HS5 cells that had either scrambled shRNA (control) or shRNA for BMP7 (shBMP7). We found that the control HS5 was able to suppress tumor growth and activated p38 and NDRG1; however, HS5 with shBMP7 significantly abrogated such an effect on CSCs and failed to suppress tumorinduced osteolysis in the tibiae ( Figure 4C ). These results suggest that BMP7 secreted from the bone stromal cells is indeed capable of inducing growth arrest of CSCs through activation of p38 and NDRG1 in the bone environment. We also assessed the effect of NDRG1 in the suppression of tumor growth by co-injecting HS5 and CSCs in which NDRG1 expression was knocked down by shRNA (shNDRG1), into mice tibiae. We found that knockdown of NDRG1 in CSCs enabled these cells to grow significantly greater than that of control CSCs even when they were co-injected with HS5 ( Figure 4D ). These results indicate that the BMP7-NDRG1 axis plays a critical role in the growth suppression of metastasized prostate tumor cells in bone, and also strongly suggest the potential therapeutic utility of BMP7 for metastatic disease.
(A) (B) (C) (D)
To directly address the possibility of using BMP7 for therapy of bone metastatic disease, 100 µg/kg of BMP7 was administrated daily through i.v. after intracardiac injection of CSCs from PC3mm or C4-2B cells to the mice. As shown in Figure 5A , BMP7 treatment significantly suppressed the bone metastasis compared to the control. Importantly, withdrawal of BMP7 treatment significantly abrogated its suppressive effect and induced recurrent metastatic growth in the bones. These results suggest that BMP7 suppresses bone metastasis by inducing senescence in disseminated CSCs in the bone. To further verify the inhibitory effect of BMP7 in the bone, CSCs were inoculated directly into mouse tibiae followed by BMP7 treatment. We found that tumor growth in tibiae was indeed significantly suppressed by BMP7 treatment compared to control ( Figure 5B ), suggesting that direct injection of BMP7 can block the growth of CSCs in the bone. Moreover, withdrawal of BMP7 treatment led the tumor to regain the ability to further proliferate in the bone. Of note, the tumor cells in tibiae exhibited feature of cellular senescence during BMP7 treatment ( Figure 5B : BMP7), whereas SA-β-gal staining was strongly decreased after withdrawal of BMP7 ( Figure 5B : Withdrawal). These results again suggest that BMP7 plays a critical role in balancing the dormancy and recurrence of CSCs in bone metastasis of prostate cancer. To accomplish Task 3, we first analyzed the BMP7 and Wnt3a expression in benign prostate tissue from healthy donors and prostate cancer tissues from patients using an existing data base. We found that BMP7 was significantly down-regulated in prostate cancer tissues compared to benign tissues. On the other hand, Wnt3a was significantly up-regulated in the prostate cancer tissues (Figure 6 ).
KEY RESEARCH ACCOMPLISHMENTS
1. We found that NDRG1 counteracts the growth promoting effect on prostate cancer cells by Wnt. 2. We found that BMP7 induces senescence by activating p38, p21 and NDRG1 in CSCs. 3. We found that BMP7-induced senescence is reversible. 
